-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 7, Hengrui Medicine issued an announcement stating that it had recently received the approval of the National Medical Products Administration to issue the "Drug Clinical Trial Approval Notice" for HR19042 capsules, and clinical trials will be launched in the near future.
On December 31, 2020, Hengrui Medicine submitted a clinical trial application for this product to the National Food and Drug Administration for the treatment of primary IgA nephropathy.
Up to now, HR19042 related research and development projects have invested about 5.